Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $191.57.

ASND has been the topic of several research reports. JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. TD Cowen decreased their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price for the company.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $130.66 on Monday. The stock has a market capitalization of $7.93 billion, a P/E ratio of -16.17 and a beta of 0.65. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00. The stock’s 50-day simple moving average is $133.63 and its 200 day simple moving average is $132.85.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S in the 3rd quarter worth approximately $30,000. Blue Trust Inc. boosted its stake in shares of Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 328 shares in the last quarter. Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at $60,000. GAMMA Investing LLC raised its position in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the period. Finally, Signaturefd LLC lifted its stake in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.